First Patient Dosed in Phase 1/2 Trial of 4DMT’s Gene Therapy 4D-310

First Patient Dosed in Phase 1/2 Trial of 4DMT’s Gene Therapy 4D-310

292069

First Patient Dosed in Phase 1/2 Trial of 4DMT’s Gene Therapy 4D-310

A Phase 1/2 clinical trial evaluating the investigational gene therapy 4D-310, developed by 4D Molecular Therapeutics (4DMT) for people with Fabry disease, has dosed its first patient. The trial (NCT04519749) is currently enrolling men with Fabry at four sites across the U.S. These study locations are the Children’s Hospital of Pittsburgh, in Pennsylvania, Emory University, in Georgia, the Baylor Scott & White Research Institute, in Texas, and the Lysosomal & Rare Disorders Research & Treatment Center, in…

You must be logged in to read/download the full post.